Clinical aspects of MuSK antibody positive seronegative MG.
about
Myasthenia gravisAcetylcholinesterase inhibitor treatment for myasthenia gravisAcetylcholinesterase inhibitor treatment for myasthenia gravisThe emerging diversity of neuromuscular junction disordersIgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravisClinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological SocietyThe role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravisPyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibodyEffects of the ß2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravisSuccessful treatment of MuSK antibody-positive myasthenia gravis with rituximab.Rapid sequence intubation without a neuromuscular blocking agent in a 14-year-old female patient with myasthenia gravis.Clinical applications of therapeutic apheresis.Introduction and overview of therapeutic apheresis.Induction of myasthenia by immunization against muscle-specific kinase.Comorbid Human Immunodeficiency Virus (HIV) and Muscle-Specific Kinase (MuSK) Myasthenia Gravis: A Case Report and Literature Review.Diagnostic utility of stimulated single-fiber electromyography of the orbicularis oculi muscle in patients with suspected ocular myasthenia.Juvenile myasthenia gravis: a paediatric perspectiveAutoantibodies to agrin in myasthenia gravis patients.LRP4 is critical for neuromuscular junction maintenanceMyasthenia gravis and Lambert-Eaton myasthenic syndrome in the same patient.Altered active zones, vesicle pools, nerve terminal conductivity, and morphology during experimental MuSK myasthenia gravisCharacterization of B cells in muscle-specific kinase antibody myasthenia gravis.Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravisThe features of myasthenia gravis with autoantibodies to MuSK.Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK.Anti-MuSK autoantibodies block binding of collagen Q to MuSK.Clinical evaluation and management of myasthenia gravis.Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling.Clinical and serological study of myasthenia gravis in HuBei Province, China.Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands.Update on respiratory management of critically ill neurologic patients.The Myotonic Plot Thickens: Electrical Myotonia in Antimuscle-Specific Kinase Myasthenia Gravis.Determination of the normative values of the masseter muscle by single-fiber electromyography in myasthenia gravis patients.Muscle autoantibodies in myasthenia gravis: beyond diagnosis?Clinical aspects of neuromuscular transmission disorders.Myasthenia gravis: a clinical-immunological update.Myasthenia gravis: Five new things.Myasthenia gravis induced by autoantibodies against MuSK.Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.
P2860
Q21202960-B1E4F830-563F-42B6-9C0F-81A2F5B90C50Q24193114-8B39FDC7-E454-4A08-96C6-E6C9F816D3C8Q24234121-9B218E74-4169-4D04-B1E3-FB02E2D49688Q24595915-75B260EB-A483-49AB-BDBB-852B21408F1FQ24648462-82E37D65-B192-4574-A8D0-2B78EAE5E679Q26765172-DFA0B73E-78A3-431E-8CF1-DD0D0A54D5CEQ27008264-017D433C-21C4-4227-9AD3-5A822A1A236DQ28286248-4813BE75-D721-4364-A786-B2874CCE4A11Q28539518-3DA7DE3C-67C1-4B70-84EB-834D08BC1208Q30320119-16A24AD3-D38E-488C-ADBA-9AE5C23DFE90Q30442775-B73C3923-D965-442A-B647-01613BA55DE8Q30451700-D2416E9C-D990-41EC-9A81-1ED7BEF32C90Q30451703-630FAE3A-1C0B-4EA1-B47D-027DF93B39F1Q30476990-B336C9DD-28C5-4E53-B08C-C06AC8333B45Q33605216-1C919362-8915-4886-A8ED-9BBA00FB7DD3Q34025447-B0DB3504-83D9-49D9-B3BE-77814B1DB92EQ34029492-CD9EC25D-60AB-4BB7-80B4-3D76CA71DF3FQ34040180-4801FC99-2A9E-4EAC-94C2-4E497D246236Q34345625-316CE9F6-E0D4-4EBB-A579-C269E61342C5Q34598509-F2B30683-C353-40BE-BBCE-1CBA05F1057FQ34599589-7A2E21E6-4886-44A1-A3EE-F86C9715D047Q35134860-68C1F5AD-BAF3-44B5-AB01-05D367E0DB20Q35487694-50B7E50E-E38A-416A-B33A-51F472B7CC63Q35489482-4FE5D31A-8B93-4A77-93B9-2B61A3E89ED1Q35495592-291E765C-0404-4E95-9B8B-EC1E5BA599A5Q35599522-4C3DC0AC-36ED-4778-87DB-87BEDDFF52A2Q35723879-393E7A07-142E-4235-9CB0-E9751F598861Q35963139-563F7ADC-E20C-44C7-8D86-AA23093A7A1CQ36044172-1A89236B-2251-4F3F-BF31-3752F90889AAQ36143252-08002427-45C8-463F-BC26-E34AB06DE423Q36143302-A5766ACF-74A2-461E-8D0B-2E82255E2496Q36303063-B9D53C37-E5B2-4442-BEBE-5014EF704050Q36378749-5FE7360D-634E-44BE-931A-76F0359CDEEEQ36412294-E4EA779B-FDE3-4CE8-8684-A6797B8A4749Q36420763-AEE2FB59-B441-4C98-A539-971D8DBED784Q36459479-CB7E2120-12CE-4CF8-B7FD-DF6EAB41B0CCQ36783864-4EE9750A-5C71-435A-B05F-387ACE12FCAAQ37040144-028E25B3-462A-4CED-962E-BD3F8F56F66BQ37223749-986DD2C7-BE75-406F-BE46-5DD13D6066A4Q37252133-5DD4F5B3-72CB-4DE8-9BB8-92F0DCF32B61
P2860
Clinical aspects of MuSK antibody positive seronegative MG.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Clinical aspects of MuSK antibody positive seronegative MG.
@en
Clinical aspects of MuSK antibody positive seronegative MG.
@nl
type
label
Clinical aspects of MuSK antibody positive seronegative MG.
@en
Clinical aspects of MuSK antibody positive seronegative MG.
@nl
prefLabel
Clinical aspects of MuSK antibody positive seronegative MG.
@en
Clinical aspects of MuSK antibody positive seronegative MG.
@nl
P2093
P1433
P1476
Clinical aspects of MuSK antibody positive seronegative MG.
@en
P2093
El-Salem K
McConville J
Sanders DB
P304
P356
10.1212/01.WNL.0000065882.63904.53
P407
P577
2003-06-01T00:00:00Z